Analyst Ratings For Lexicon Pharmaceuticals (NASDAQ:LXRX)
Today, Cowen and Company reiterated its Hold rating on Lexicon Pharmaceuticals (NASDAQ:LXRX).
There are 1 hold rating, 5 buy ratings on the stock.
The current consensus rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) is Buy (Score: 2.83) with a consensus target price of $28.00 per share, a potential 75.00% upside.
Some recent analyst ratings include
- 8/1/2017-Cowen and Company Reiterated Rating of Hold.
- 4/5/2017-Needham & Company LLC Reiterated Rating of Buy.
- 5/5/2016-J P Morgan Chase & Co Reiterated Rating of Hold.
- On 6/6/2016 James F Tessmer, VP, sold 1,500 with an average share price of $15.00 per share and the total transaction amounting to $22,500.00. View SEC Filing
- On 5/23/2016 James F Tessmer, VP, sold 6,000 with an average share price of $13.00 per share and the total transaction amounting to $78,000.00. View SEC Filing
- On 12/12/2014 C.V. Invus, Director, bought 150,000 with an average share price of $0.88 per share and the total transaction amounting to $132,000.00. View SEC Filing
- On 12/10/2014 C.V. Invus, Director, bought 315,896 with an average share price of $0.90 per share and the total transaction amounting to $284,306.40. View SEC Filing
- On 11/26/2014 International S.C.A. Artal, Director, bought 149,253,731 with an average share price of $1.01 per share and the total transaction amounting to $150,746,268.31. View SEC Filing
- On 10/23/2012 International S.C.A. Artal, Director, bought 3,000,000 with an average share price of $2.25 per share and the total transaction amounting to $6,750,000.00. View SEC Filing
Recent Trading Activity for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Shares of Lexicon Pharmaceuticals closed the previous trading session at 16.00 down -0.30 -1.84% with 734,671 shares trading hands.